Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
暂无分享,去创建一个
A. Stamatoullas | S. Chevret | B. Quesnel | S. Cuzzubbo | P. Fenaux | T. Cluzeau | M. Sébert | L. Adès | C. Récher | J. Lehmann-Che | C. Berthon | I. Madelaine | A. Carpentier | E. Raffoux | D. Sallman | R. Komrokji | A. Walter-petrich | O. Rauzy | Ramy Rahmé | P. Peterlin | M. Loschi | E. Miekoutima | L. Willems | R. Rahmé | B. Bève | H. Attalah | Fatiha Chermat | A. Walter-Petrich
[1] J. Esteve,et al. AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A , 2020 .
[2] A. Letai,et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.
[3] M. Konopleva,et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. , 2020, Blood advances.
[4] Qi Zhang,et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.
[5] A. Stamatoullas,et al. APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM) , 2019, Blood.
[6] Jiqiang Yao,et al. Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) , 2019, Blood.
[7] P. Fenaux,et al. Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia , 2019, Haematologica.
[8] E. Padron,et al. TP53 and therapy-related myeloid neoplasms. , 2019, Best practice & research. Clinical haematology.
[9] P. Campbell,et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups , 2019, Leukemia.
[10] M. Konopleva,et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. , 2019, The Lancet. Haematology.
[11] K. Patel,et al. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. , 2018, Blood.
[12] G. Garcia-Manero,et al. Decitabine in TP53-Mutated AML. , 2017, The New England journal of medicine.
[13] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[14] S. Nahas,et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.
[15] C. Preudhomme,et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.
[16] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[17] G. Mufti,et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis , 2013, British journal of haematology.
[18] G. Juliusson,et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[20] Jan Bergman,et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. , 2009, Cancer cell.
[21] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[22] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[23] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.